FDA rejects Capricor's DMD cell therapy, citing need for more data
TL;DR Summary
The FDA rejected Capricor Therapeutics' application for its cell therapy deramiocel aimed at treating Duchenne muscular dystrophy, citing insufficient evidence of effectiveness and requesting more clinical data.
- FDA rejects Capricor’s cell therapy for Duchenne muscular dystrophy STAT
- Capricor shares sink as US FDA declines to approve cell therapy Reuters
- FDA rejects approval of Capricor's cell therapy for DMD FirstWord Pharma
- Capricor Shares Sink After FDA Rejects Drug for Muscle Disease Bloomberg
- FDA rejects Capricor’s DMD cell therapy, asks for more data Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
87%
210 → 27 words
Want the full story? Read the original article
Read on STAT